Vanguard Capital Wealth Advisors Purchases 412 Shares of Pfizer Inc. (NYSE:PFE)

Vanguard Capital Wealth Advisors lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.2% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 10,217 shares of the biopharmaceutical company’s stock after purchasing an additional 412 shares during the period. Vanguard Capital Wealth Advisors’ holdings in Pfizer were worth $284,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Pfizer during the 4th quarter worth approximately $2,129,927,000. Wellington Management Group LLP boosted its holdings in shares of Pfizer by 4.9% during the 4th quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock worth $6,886,849,000 after buying an additional 11,099,024 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Pfizer by 8.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 104,246,432 shares of the biopharmaceutical company’s stock worth $2,985,783,000 after purchasing an additional 8,473,686 shares during the period. Massachusetts Financial Services Co. MA increased its position in Pfizer by 13.8% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 68,506,441 shares of the biopharmaceutical company’s stock worth $1,972,300,000 after buying an additional 8,298,920 shares during the period. Finally, Ruffer LLP raised its stake in Pfizer by 248.7% in the 4th quarter. Ruffer LLP now owns 5,796,012 shares of the biopharmaceutical company’s stock worth $166,837,000 after purchasing an additional 4,133,786 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday. Morgan Stanley increased their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. BMO Capital Markets restated an “outperform” rating and set a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Finally, Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Ten analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $35.86.

Pfizer Stock Up 0.5 %

Shares of NYSE:PFE traded up $0.14 on Friday, reaching $27.94. The company had a trading volume of 3,814,304 shares, compared to its average volume of 40,672,027. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $158.32 billion, a PE ratio of -463.26, a PEG ratio of 1.08 and a beta of 0.70. The firm’s 50 day simple moving average is $27.81 and its 200-day simple moving average is $27.69. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $37.80.

Pfizer (NYSE:PFE) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. During the same quarter in the prior year, the firm earned $1.23 earnings per share. Pfizer’s revenue for the quarter was down 19.5% on a year-over-year basis. As a group, analysts expect that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.01%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s dividend payout ratio is currently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.